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A B S T R A C T
Resistance to chemotherapy is a challenging problem for treatment of cancer patients and autophagy has been
shown to mediate development of resistance. In this study we systematically screened a library of 306 known
anti-cancer drugs for their ability to induce autophagy using a cell-based assay. 114 of the drugs were classified
as autophagy inducers; for 16 drugs, the cytotoxicity was potentiated by siRNA-mediated knock-down of Atg7
and Vps34. These drugs were further evaluated in breast cancer cell lines for autophagy induction, and two
tyrosine kinase inhibitors, Sunitinib and Erlotinib, were selected for further studies. For the pharmacological
inhibition of autophagy, we have characterized here a novel highly potent selective inhibitor of Vps34, SB02024.
SB02024 blocked autophagy in vitro and reduced xenograft growth of two breast cancer cell lines, MDA-MB-231
and MCF-7, in vivo. Vps34 inhibitor significantly potentiated cytotoxicity of Sunitinib and Erlotinib in MCF-7 and
MDA-MB-231 in vitro in monolayer cultures and when grown as multicellular spheroids. Our data suggests that
inhibition of autophagy significantly improves sensitivity to Sunitinib and Erlotinib and that Vps34 is a pro-
mising therapeutic target for combination strategies in breast cancer.
1. Introduction
Development of drug resistance and/or intrinsic failure to respond
to drug treatment represent major obstacles in clinical oncology.
Macroautophagy (autophagy) represents an important pathway among
the several mechanisms adopted by cancer cells to overcome cytotoxi-
city of anticancer agents [1,2]. Autophagy is a catabolic degradative
pathway highly conserved through evolution, with its primary role as a
survival process [3]. Organelles (damaged and/or redundant), protein
aggregates, mitochondria, lipids, invading pathogens and other cyto-
plasmic material are engulfed by a double-membrane-surrounded au-
tophagosome which fuses with a lysosome [4]. In the auto-lysosome,
the cargo material is degraded by hydrolases and returned to the cy-
tosol to support macromolecular biosynthesis and cellular metabolism.
Autophagy is considered to be a protective cellular mechanism against
many human pathologies, including cancer, neurodegeneration, in-
flammation and infectious diseases [5]. Modulation of autophagy is
being evaluated as a therapeutic strategy in some pathological
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conditions [6]. Interestingly, the role of autophagy in cancer biology
seems to be context-dependent. Cell-autonomous autophagy may play a
protective role by maintaining cellular homeostasis and reducing da-
mage from oxidative stress. In many advanced cancers, autophagy
supports tumor growth by promoting adaptation to environmental and
metabolic stress [1,7]. Recently, an important pro-tumorigenic role has
also been demonstrated for non-cell autonomous (or microenviron-
mental) autophagy [8].
In several in vitro and in vivo models, autophagy was found to
contribute to the development of resistance to chemo- and radiotherapy
[9]. These preclinical findings have prompted clinical trials testing the
addition of anti-malaria drugs chloroquine (CQ) or hydroxychloroquine
(HCQ) to enhance the efficacy of different cancer treatments [7,10]. For
example, high levels of autophagy are associated with the development
of resistance to BRAF inhibitors [11] and the combination of vemur-
afenib with CQ showed important clinical benefits [12]. Recent studies
have also indicated that autophagy is involved in breast cancer biology
[13,14] and in the development of therapy resistance in breast cancer
[15,16].
Vps34 is a class III phosphatidylinositol-3-kinase (PI3K) catalyzing
the phosphorylation of phosphatidylinositol at the 3′ position of the
inositol ring to produce phosphatidylinositol 3-phosphate (PI3P). The
lipid kinase activity of VPS34 is fundamental for the biogenesis of au-
tophagosomes since proteins containing a PI3P-binding domain (like
FYVE, PROPPIN or PX domain) are recruited to the nascent phagophore
and contribute to the maturation of autophagosomes [17]. Vps34 pro-
motes the development of breast cancer [18,19] and has recently been
identified as a target to inhibit autophagy [20–22].
In this study, we performed a high-content screening using a library
of anticancer drugs currently used preclinically and clinically and
identified drugs inducing autophagy. We further assessed whether
pharmacological or RNAi-mediated autophagy inhibition potentiated
the cytotoxic effects of autophagy-inducing drugs, among them
Sunitinib and Erlotinib. Moreover, we describe for the first time a novel,
highly potent and selective small molecule inhibitor of Vps34,
SB02024, that efficiently inhibited autophagy and cell viability of
breast cancer cells in vitro and in vivo, and when combined with
Sunitinib, enhanced its cytotoxic effects in both conventional cell cul-
tures and in multicellular spheroids of breast cancer cell lines.
2. Materials and methods
2.1. Cell culture
HOS cells stably expressing GFP-LC3 (a kind gift from Gerald
McInerney, Karolinska Institutet) were cultured in DMEM containing
10% fetal bovine serum (FBS) [23]. MDA-MB-231 cells and MDA-MB-
231 cells stably expressing GFP-LC3 were grown in DMEM supple-
mented with 10% FBS and 1% non-essential amino acids (NEAA). MCF-
7 cells were cultured in RMPI-1640 medium containing 10% FBS, 1%
NEAA, 1mM sodium pyruvate and 10 μg/mL insulin. MCF-7 cells stably
expressing RLuc-LC3wt or RLuc-LC3G120A (a kind gift from Marja
Jäättelä, Danish Cancer Society) [24] were cultured in RPMI-1640
medium with 10% FBS. H1299 cells were maintained in RPMI-1640
medium with 20% FBS. All cell lines were cultured with antibiotics. All
products were purchased from Thermo Scientific. MDA-MB-231, MCF-7
and H1299 were purchased from the American Tissue Culture Collec-
tion (ATCC). MDA-MB-231 expressing GFP-LC3 were kindly provided
by from Yangqing Xu (Harvard Medical School, Boston, MA). Cell lines
were tested using the ATCC cell line authentication service and routi-
nely tested for Mycoplasma. All cell lines were maintained at 37 °C with
5% CO2.
2.2. GFP-2xFYVE expressing H1299 cells
H1299 cells were infected with a lentiviral vector encoding a GFP-
2xFYVE construct (Vectalys) consisting of GFP protein tagged with two
repeats of a sequence corresponding to the FYVE domain of the Hrs
protein at the Ct end and separated by a linker. Infection was carried
out according to manufacturer's protocol at 0.3–0.6 multiplicity of in-
fection (MOI) followed by puromycin selection and FACS sorting.
2.3. Chemicals and compound library
Bafilomycin A1 (BafA1, #B1793) and Chloroquine (CQ, #C6628)
were purchased from Sigma. Ku-0063794 (KU, #S1226), Sunitinib
(#S1042), Erlotinib (#S1023) and PIK-III (#S7683) were purchased
from Selleckchem. The compound library was obtained from High
Throughput Biomedicine (HTB) unit at the Institute for Molecular
Medicine Finland (FIMM) and contained U.S. Food and Drug
Administration/European Medicines Agency (FDA/EMA)-approved
oncology drugs (n=129), as well as emerging investigational and
preclinical compounds (n= 177) covering a wide range of molecular
targets (Supplementary Table 1). Compounds were received diluted in
dimethyl sulfoxide (DMSO) or water at different concentrations de-
pending on their biological activity. For screening purposes, compound
stocks were dispensed from Labycyte 384 LDV plates to V-bottom
Greiner plates using an Echo 555 acoustic liquid handler (LabCyte) and
diluted in cell culture medium.
2.4. High-content screen of autophagy modulation
HOS cells stably expressing GFP-LC3 were plated at a density of
1000 cells/well in 384-well imager quality black clear bottom plates
(BD Falcon) using a Multidrop dispenser (Thermo Scientific). The fol-
lowing day, the compound library was dispensed using the Bravo liquid
handling system (Agilent). DMSO or 10 μM KU (positive control) were
manually added using a multichannel pipette. Cells were treated in
duplicate for 4, 8 or 16 h and 10 nM BafA1 was added for the last hour
of treatment [25]. Cells were fixed and stained in 4% paraformaldehyde
(PFA) with 25mg/mL Hoechst 33342 (Sigma, #B2261) followed by
washing steps. Images (4/well) were captured on Operetta® High Con-
tent Imaging System (Perkin Elmer) using a 20X LWD objective in wide-
field fluorescence mode in 2 fluorescent channels (Em.360–340/
Ex.410–480, Hoechst 3334; Em.360–340/Ex.410–480 and
Em.460–490/Ex.500–550 for GFP-LC3) and further analysed using
Columbus 2.4 analysis software (PerkinElmer). “Find Nuclei Building
Block” algorithm was applied to identify Hoechst-33342-labeled nuclei
and was then used as a seeding point to identify cytoplasm with “Find
Cytoplasm Building Block”. “Find Spots Building Block” was applied to
identify GFP aggregates for measurement of LC3 incorporation into
autophagosomes/autolysosomes. “Calculate Intensity Properties Building
blocks” was used to determine cell number and GFP-LC3 puncta/cell.
The results were exported as mean values/well. Z′ factor values for each
plate for different quantification parameters were calculated using
Columbus tertiary analysis. Data were visualized using Spotfire soft-
ware.
For high content fluorescent microscopy beyond the screening,
images (6/well) were captured on ImageXpress Micro (Molecular
Devices) and analysed using the MetaXpress software (Molecular
Devices). “Transfluor” algorithm was applied to identify Hoechst-
33342-labeled nuclei and GFP-LC3 puncta area/cell. Results were ex-
ported as mean values/well. Data were visualized using GraphPad
(Prism).
2.5. Western blotting
Cell pellets were lysed in lysis buffer (50mM Tris, 150mM NaCl,
1 mM EDTA, 1% Triton X-100, 1% glycerol, adjusted to pH 8) supple-
mented with protease and phosphatase inhibitors (Roche) and 1mM
DTT. Protein concentration was determined by Pierce BCA Protein
Assay (Thermo Scientific) and equal amount of proteins were loaded on
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4–12% Bis-Tris gels (NuPAGE, Thermo Scientific). After transfer, PVDF
membranes were blocked in 5% milk in TBST (0.05% Tween-20) and
incubated with primary antibodies overnight at 4 °C. Membranes were
incubated for 1 h at room temperature with appropriate HRP-con-
jugated secondary antibodies and binding was revealed using the ECL
system (#34577, Thermo Scientific). Antibodies against p62 (#5114)
and LC3B (#2775) were purchased from Cell Signalling Technologies,
NCOA4 (#sc-20011) from Santa Cruz Biotechnologies, Vps34
(#GTX129528) from GeneTex, β-actin (#A5441) from Sigma, goat anti-
rabbit HRP (#A16110) and goat anti-mouse HRP (#A16078) from
Thermo Scientific.
2.6. Cell viability assays
HOS cells were plated and simultaneously reverse-transfected using
HiPerFect transfection reagent (Qiagen) with non-targeting 25 nM
siScramble (siSCR; D-001810-10-20, Dharmacon) or 25 nM siRNA tar-
geting ATG7 (L-020112-00-0005, Dharmacon) and VPS34 (L-005250-
00-0005, Dharmacon) specified as siATG7/siVPS34. The day after
transfection, drugs were added, and viability was measured 48 and 72 h
after treatment using the CellTiter-Glo assay (Promega).
MDA-MB-231 (5× 103 cells/well) and MCF-7 (2.5×103 cells/well)
cells were plated in 96-well plates and treated with compounds the
following day. Viability was measured 72 h after treatment using the
acid phosphatase (APH) assay [26] for MDA-MB-231 or the CellTiter-
Glo assay for MCF-7 following the manufacturer's instructions.
2.7. Clonogenic assay
Cells were plated at a density of 500 cells/well in 6-well plates and
treated with compounds the following day. Three days after treatment
medium was replaced with drug-free medium. After growing for an-
other three days, colonies were fixed in 4% PFA and stained with 0.05%
Crystal violet. The ImageJ-plugin ‘‘ColonyArea’’ optimized for quanti-
tative analysis of foci formation assays was used as previously reported
[27].
2.8. Formation and viability of multicellular spheroids
Multicellular spheroids (MCS) from MDA-MB-231 and MCF-7 cells
were prepared as previously described [28]. Briefly, cells were plated in
100 μL medium in round bottom, ultra-low attachment 96-well plates
(Costar, #7007). MCS from MCF-7 cells (1× 104 cells/well) were ob-
tained by leaving the plate at RT for 30min to sediment cells before
moving into the incubator. MDA-MB-231 cells (5× 103 cells/well)
were resuspended in medium supplemented with 0.24 μg/μL Geltrex™
LDEV-Free Reduced Growth Factor Basement Membrane Matrix
(#A1413202, Thermo Scientific) and centrifuged for 15min at
1000×g at 4 °C. The medium of four-days-old MCS was replaced with
fresh medium containing different combinations of drugs and com-
pounds. Cell viability was assessed three days after treatment using the
CellTiter Glo 3D assay (Promega).
2.9. In vivo experiments
MDA-MB-231 cells (5× 106) resuspended in PBS with Matrigel
(1:1) were subcutaneously implanted in the lower abdomen of female
SCID-Beige mice (5–6 weeks of age). MCF-7 cells (1× 107) resuspended
in PBS with Matrigel (1:1) were inoculated in the mammary fat pad of
NOD/SCID mice. Mice were randomized into groups of 5–10 mice/
group. SB02024 was administered orally once daily. Control animals
received the vehicle. Body weight and clinical symptoms were recorded
daily. Tumor volume was measured three times a week using a digital
caliper (V= 0.5 × length × width [2]). Experiments with MDA-MB-
231 and MCF-7 xenografts were performed by GVK Bio (Hyderabad,
India) and Crown Bioscience (Beijing, China), respectively. Procedures
involving the care and use of animals were approved by the Vivo Bio-
Tech animal ethics committee (VB/IAEC/01/2016/129/Mice/SCID)
and IACUC committee of CrownBio (AN-1702-013-736).
2.10. Determination of off-target kinase activity and compound Kd
SB02024 and PIK-III were tested on the KINOMEscan™ platform
(DiscoverX, Fremont, CA) as previously described [29]. SB02024 and
PIK-III were tested at 1 μM concentration in the ScanEDGE™ kinase
assay panel containing 97 kinases. SB02024 was further tested 1 μM
concentration in the ScanMAX™ kinase assay including a larger set of
468 kinases. Inhibitor binding constants (Kd values) for PIK-III and
SB02024 were determined for 9 relevant kinases (PIK3C3, PIK3CA,
PIK3CB, PIK3CD, PIK3CG, mTOR, PIK3C2B, PIK3C2G, PIKFYVE) with a
top screening concentration of 30 μM.
2.11. Statistical analysis
Statistical analysis was performed with GraphPad (Prism).
Comparisons between groups were performed using a two-tailed un-
paired t-test. P-values of< 0.05 (*),< 0.01 (**), < 0.001 (***) were
determined to be statistically significant. Sample size (n) refers to
biological replicates unless stated otherwise.
Primary screening of the drugs was calculated with ANOVA [30]
using the R software package (https://www.R-project.org/). Drugs that
had a significantly higher activity (p < 0.05) when treated with BafA1
in comparison to cells without BafA1 were classified as inducers of
autophagy, whereas drugs that did not have such a significantly higher
activity in the presence of BafA1 in comparison to cells without BafA1,
but still had a significantly higher activity (p < 0.05) in comparison
with the negative control, were classified as blockers.
3. Results
3.1. Modulation of autophagy by anticancer drugs: primary and secondary
screening
A major aim of this study was to identify autophagy-inducing an-
ticancer drugs whose cytotoxic activity can be potentiated by inhibiting
autophagy. To measure the effect of known anti-cancer drugs on the
autophagic turnover we employed a high content screening assay using
the osteosarcoma cell line HOS stably expressing GFP-LC3 fusion pro-
tein (Fig. 1A). Upon activation of autophagy, the lipidated form of LC3
protein (LC3-II) accumulates in autophagosomes which are visible as
GFP + puncta. Inhibition of the autophagic flux by BafA1 blocks the
acidification of lysosomes and therefore the final degradation of GFP-
LC3, thus further increasing the number of GFP-LC3+ puncta. Ku-
0063794 (KU), a mTOR inhibitor previously described to activate au-
tophagy [31] served as a positive control. The images were quantified
and the number, as well as the area, of fluorescent puncta per cell were
calculated (Supplementary Fig. S1A). Although the autophagy-mod-
ulating activity of drugs may be cell line and/or tumor type dependent,
these types of cellular systems are easy, robust and have been fre-
quently used for screening purposes. The screening was carried out on a
library of anti-cancer drugs and drug candidates routinely used for
precision medicine at FIMM [32–34]. An overview of the complete
screening procedure is shown in Fig. 1A. Initially, compounds were
tested at a 1000-fold dilution of the stock at three time points: 4, 8 and
16 h in the absence or presence of BafA1, which was added 1 h before
the fixation and nuclear staining. Fig. 1B shows results obtained after
quantification of images acquired after 8 h of incubation with the drugs.
The average of GFP-LC3 puncta/cell were normalized to the values
obtained with KU as a positive control (100% autophagy induction).
Screening quality was overall good as assessed by a Z prime factor of
0.59 ± 0.15. We applied a threshold (mean + 3X SD of the DMSO-
treated samples) to identify active molecules. Separate thresholds were
M. Dyczynski et al. Cancer Letters 435 (2018) 32–43
34
calculated for each time point and for both screening conditions and
relatively applied to the sample values measured for drug alone and in
presence of BafA1 (Supplementary Fig. S1B). The compound library
was then subjected to the confirmation screening performed at three
different concentrations (1,000, 10,000 and 100,000-fold stock dilu-
tion) and at three time points in the absence or presence of BafA1 in
accordance with the primary screening (Supplementary Fig. S1C). The
primary screening data correlated well to the data obtained in the
confirmation screening (Figs. 1C) with only 8 substances failing to be
confirmed.
Drugs were classified as autophagy inducers, autophagy blockers or
as negatives (Supplementary Table 1) based on their significant activity
(p < 0.05) in the presence or absence of BafA1 or in comparison with
the negative control, as described earlier. In total 114 drugs, out of 304
in the drug library, were classified as inducers of autophagy. Among
known autophagy inducers, we found mTOR, Chk1 and HDAC in-
hibitors [35], thus, validating our results (Supplementary Table 1).
3.2. Modulation of cell viability by autophagy inhibition: cytotoxicity
screening
We next aimed to investigate if inhibition of autophagy would
modulate sensitivity to the identified autophagy-inducing drugs. For
this purpose, we chose to inhibit ATG7 and VPS34, two autophagy
genes crucial for autophagosome formation and maturation. RNAi-
mediated knockdown of ATG7 and VPS34 (alone or in combination)
resulted in significantly reduced expression of the specific mRNA
compared to cells treated with siSCR in HOS-GFP-LC3 cells (Fig. 2A).
The double knockdown was selected as this condition reduced GFP-
LC3+ puncta of both basal and KU-induced autophagy more efficiently
(Fig. 2B and C). We assessed cell viability of siRNA-transfected cells
treated with the drug library at three different concentrations (Fig. 2D
and Supplementary Fig. S2A). For each drug, we calculated the ratio of
viability between siATG7/VPS34 versus siSCR, with a ratio< 1 in-
dicating increased cytotoxicity in cells with inhibited autophagy. As a
result, we found that among the 114 drugs classified as autophagy in-
ducers, 16 drugs had increased cytotoxic activity upon genetic inhibi-
tion of autophagy (threshold < 0.8) (Fig. 2D).
3.3. Sunitinib and Erlotinib modulate autophagic flux in breast cancer cell
lines
Human breast carcinomas are particularly sensitive to inhibition of
autophagy [14,36,37] and preclinical, as well as clinical, evidence
suggests that autophagy inhibition may improve response to treatments
in breast cancer [16,38]. Therefore, we evaluated if the drugs – in-
ducers of autophagy - identified in the toxicity screening would also
induce autophagy in breast cancer cells. Six out of the 16 inducers
identified in HOS-GFP-LC3 cells also induced autophagy in the MDA-
MB-231 GFP-LC3 cells. This was evident by an increased number of
GFP-LC3+ puncta in the presence of BafA1 as compared to drug
treatment alone (Fig. 3A). Among these, Sunitinib and Erlotinib have
shown a promising pre-clinical but a limited efficacy in the treatment of
breast cancer patients [39,40]. Therefore, these drugs were chosen for
further investigation with the aim to explore whether the combination
with autophagy inhibition would improve their efficacy. Titration of
Sunitinib in MDA-MB-231-GFP-LC3 revealed an induction of autophagy
and autophagic flux at low, clinically relevant concentrations (Fig. 3B,
Supplementary Fig. S3A). Titration of Erlotinib increased autophagic
flux as well, although not to the same extent as Sunitinib
(Supplementary Fig. S3B). Interestingly, Sunitinib seemed to inhibit
autophagic flux at the highest concentration tested (20 μM) indicated
by a no further increase of GFP-LC3 puncta in the presence of BafA1
(Fig. 3B). This was confirmed in another breast cancer cell line, MCF-7-
GFP-LC3, which showed similar effects of Sunitinib on autophagic flux
(Fig. 3C). This probably reflects the ability of Sunitinib to localize to the
lysosomes and to inhibit lysosomal degradation at higher concentra-
tions [41]. We have chosen a concentration of 3 μM for further ex-
periments. The specificity of autophagy induction was confirmed using
MCF-7 cells ectopically expressing a GFP-LC3 G120A, a mutant LC3
unable to localize to the autophagosomes [24] and therefore failing to
accumulate GFP-positive foci (Supplementary Fig. S3C, D). Next, in-
duction of autophagic flux by 3 μM Sunitinib was analysed using au-
tophagy markers LC3B, NCOA4 and p62 21,25 by Western blotting
(Fig. 3D and E). Sunitinib induced accumulation of LC3B-II protein
levels, as well as of NCOA4 and p62 in the presence of BafA1 in MCF-
7 cells (Fig. 3E) while these effects were not pronounced in MDA-MB-
231 cells (Fig. 3D). This is likely due to high basal autophagic rate in
these cells as compared to MCF-7 (compare LC3B-II levels and LC3-I vs.
LC3B-II levels in Fig. 3D and E). Neither p62 nor NCOA4 was sig-
nificantly changed in MDA-MB-231 cells at 6 h of Sunitinib treatment
while NCOA4 levels clearly elevated after 24 h of Sunitinib treatment
(Fig. 3D and E). This could be due to lysosomal targeting by Sunitinib
shown by previous reports [24] or an autophagy-independent
Fig. 1. Screening of anticancer drug library for induction of autophagy.
(A) Flowchart depicting the screening procedure. Primary and secondary
(confirmation) screens of the FIMM oncology collection drug library was per-
formed in HOS osteosarcoma cell line expressing GFP-LC3 using high-content
screening fluorescence microscopy. Toxicity screen was conducted in the same
cell line where autophagy was inhibited by RNAi with Vps34 and Atg7, using
viability assay (Fig. 2). (B) Scatter plot of the results of the primary screening.
HOS-GFP-LC3 cells were treated with DMSO (red), library compounds (blue), or
10 μM KU-0063794 (KU), used as a positive control (green), for 8 h; 10 nM
Bafilomycin A1 (BafA1) was added for the last hour of treatment. The number
of GFP + puncta per cell was recorded as described in M&M and set as 0%
activity in cells treated with DMSO and as 100% activity in cells treated with
KU. The percent of relative activity in the presence of BafA1 (y-axis) was plotted
against relative activity in the absence of BafA1 (x-axis). The dashed lines in-
dicate respective thresholds applied for identification of active drugs. (C)
Correlation of data obtained in primary and confirmation screenings of the drug
library (at 1000 fold dilution) tested alone (upper panel) or in the presence of
BafA1 (lower panel).
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regulation of NCOA4 expression [41,42]. Thus, the extent of autophagy
induction by Sunitinib appears to be dose- and cell line-dependent.
3.4. Novel small molecule Vps34 inhibitor SB02024 inhibits autophagic flux
To evaluate the potential application of pharmacological autophagy
inhibition in combination treatment of breast cancer we explored tar-
geting Vps34. A number of small molecular inhibitors of Vps34 have
previously been published, including PIK-III [21,43]. Here, we present
the biological activities of SB02024, a novel, potent and selective Vps34
inhibitor whose chemical and pharmacological properties will be de-
scribed elsewhere (manuscript in preparation) in comparison to PIK-III.
SB02024 was selected from a series of compounds with high bio-
chemical potency inhibiting Vps34, which in turn was shown to have
the ability to inhibit autophagy in cellular systems (patents WO/2017/
140841 and WO/2017/140843). SB02024 is a highly potent Vps34
inhibitor (Kd= 1 nM) and more than 1000 times selective towards the
other PI3K isoenzymes (Table 1) as well as highly selective at 1 μM in
the DiscoveRx ScanMax panel of 468 kinases (Supplementary Fig. S4A).
Comparing to the previously published Vps34 inhibitor PIK-III
(Kd= 0.3 nM), we found that SB02024 has a similar selectivity profile
for the PI3K isoenzymes, except for PIK3CG, where SB02024 is 40 times
more selective (Table 1). Also, SB02024 is more selective than PIK-III in
the ScanEDGE kinase panel (Supplementary Fig. S4B). Similarly to PIK-
III [21], SB02024 is an ATP competitive inhibitor and binds in the
active site of Vps34 thus inhibiting its catalytic function.
Considering the crucial role of Vps34 in the autophagic machinery,
we examined the effect of Vps34 inhibition on PI3P production and
autophagy. With FYVE being a PI3P-specific lipid-binding domain, we
generated H1299 cells stably expressing a GFP-2xFYVE construct to
measure the effect of Vps34 inhibition on PI3P distribution (Fig. 4A and
B). RNAi with VPS34 dramatically reduced GFP-2xFYVE puncta under
basal conditions or when autophagy was induced by either Ku or amino
acid starvation (Supplementary Fig. S4C). Consistent with the RNAi
knockdown, pharmacological treatment with SB02024 also reduced the
number of GFP-2xFYVE puncta in a dose-dependent manner
(IC50= 14 nM) (Fig. 4A and B). Inhibition of Vps34 activity using small
molecular weight compounds is expected to block autophagy, as pre-
viously reported for PIK-III [21]. We, therefore, investigated if the in-
duction of autophagy by mTOR inhibitor KU can be prevented by Vps34
inhibition with SB02024. In HOS-GFP-LC3 cells, SB02024 inhibited KU-
induced GFP-LC3+ puncta formation in a dose-dependent manner
(Fig. 4C and D). To gain further insight into the impact of SB02024 on
autophagy, we analysed the expression of autophagy markers and their
degradation rate in MDA-MB-231 and MCF-7 cells treated with in-
creasing concentrations of SB02024 for 24 h in the presence or absence
of BafA1 during the last 2 h of treatment (Fig. 4E and F, respectively).
We observed that SB02024 induced a dose-dependent increase in levels
of NCOA4 and p62 which are not further modulated by BafA1, sug-
gesting that Vps34 inhibition blocks the turnover of autophagy sub-
strates (Fig. 4E and F). In line with this observation, total levels of LC3-
II were slightly increased by SB02024 and the turnover of LC3-II was
also completely inhibited (Fig. 4E and F). We did not observe any
changes in the expression of the Vps34 protein upon treatment with
SB02024 (Fig. 4E and F). Furthermore, electron microscopy analysis of
MDA-MB-231 cells treated with Vps34 inhibitors PIK-III and SB02024
revealed the presence of large empty vacuoles or vacuoles filled with
smaller vesicles and undigested electron-dense material. These struc-
tures likely represent swollen endolysosomal vesicles, as previously
described in cells lacking Vps34 (Supplementary Fig. S4D) [44].
3.5. VPS34 inhibitor SB02024 inhibits tumor growth in vivo
Recently, several small molecule Vps34 inhibitors have been de-
scribed [43]. Yet, in vivo anticancer activity has only been reported for
the compound SAR-405, which failed to reduce tumor growth in a xe-
nograft model of human head and neck cancer [45]. Following the
results obtained in vitro, we investigated the effects of SB02024 treat-
ment in vivo in mice bearing MDA-MB-231 or MCF-7 xenografts (Fig. 4G
and H, respectively). Mice were treated for 30 (MDA-MB-231) or 21
(MCF-7) days with SB02024 (20 and 50mg/kg) given by oral gavage.
SB02024 treatment reduced significantly tumor growth at the dose of
50mg/kg at termination in both tumor models (Fig. 4G and H). In line
with this, tumor weight was significantly reduced following 50mg/kg
SB02024 treatment for MDA-MB-231 (Supplementary Fig. S4E). This
was not the case for the MCF-7 xenografts, and one possible explanation
is the lower number of animal (5/group) in the MCF-7 study and the
occurrence of one death one day before termination in the group
treated with 50mg/kg of SB02024. Importantly, SB02024 treatment























































































































Fig. 2. Modulation of cell viability by autophagy in-
hibition: cytotoxicity screening.
HOS-GFP-LC3 cells were transfected with 25 nM siRNA
targeting ATG7, VPS34, ATG7/VPS34 or non-targeting
siRNA Scramble (siSCR) and treated with the drugs from
the FIMM library. (A) Gene expression levels of ATG7 and
VPS34 measured by qRT-PCR 48 h after transfection with
indicated siRNA. Means + SD of triplicates are shown.
(B) Quantification of GFP + puncta area after treatment
with DMSO, 10 nM Bafilomycin A1 (BafA1), 10 μM KU-
0063794 (KU) or a combination of both BafA1 + KU
(n = 3). Means + SD are shown, ***P < 0.001, two-
tailed unpaired t-test. (C) Fluorescence microscopy
images of cells transfected with either siSCR or siATG7/
VPS34 and treated with BafA1 + KU. Hoechst nuclear
stain (blue), LC3-GFP (green), or merge of both channels
are shown. Scale bar: 50 μm. (D) Scatter plot of the results
of the cytotoxicity screen. siRNA-transfected cells were
treated with DMSO or drugs that induced autophagy in
the secondary screen for 72 h. Viability was measured
using CellTiter Glo assay. Compounds selected for further
validation are denoted in red. The percentage of viable
cells in siSCR transfected (x-axis) versus siATG7/VPS34
transfected (y-axis) cells are plotted.
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Fig. 3. Sunitinib modulates autophagic flux in breast cancer cell lines.
(A) MDA-MB-231 cells expressing GFP-LC3 were treated with DMSO, KU-0063794 (KU) as a control, or specified drugs at indicated concentrations for 6 h; 20 nM
Bafilomycin A1 (BafA1) was added for the last 2 h of treatment. GFP + puncta area was quantified as described in M&M. Six compounds on the right side of the grey
dotted line were identified as autophagy inducers. Means ± SD of triplicates are shown. (B, C) Quantification of GFP + puncta area of MDA-MB-231 (B) and MCF-7
(C) expressing GFP-LC3 treated with DMSO, KU or Sunitinib at indicated concentrations for 6 h; 20 nM BafA1 was added for the last 2 h of treatment. Means + SD of
triplicates are shown. (D, E) MDA-MB-231 (D) and MCF-7 (E) cells were treated with 3 μM Sunitinib or DMSO for 6 and 24 h; 50 nM BafA1 was added for the last 2 h
of incubation. Autophagic flux was measured by assessing levels of NCOA4, p62, and LC3B-II using Western blotting. β-actin was used as a loading control. A
representative blot of two independent experiments is shown. Quantification using Image J is indicated below images and represents the mean of two independent
experiments. Sample loading on upper and lower membrane originated from the same protein lysate.
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symptoms of toxicity (Supplementary Fig. S4F). This data pointed at the
in vivo antitumor efficacy of SB02024 treatment.
3.6. Vps34 inhibitors increase the sensitivity of MDA-MB-231 and MCF-
7 cells to tyrosine kinase inhibitors
Since inhibition of autophagy can increase the cytotoxic activity of
several anticancer therapeutic agents, including tyrosine kinase in-
hibitors (TKI) [10,46], we further investigated whether treatment with
the Vps34 inhibitors SB02024 and PIK-III would increase the sensitivity
of MDA-MB-231 and MCF-7 cells to Sunitinib and Erlotinib. In these
experiments, CQ was used in parallel as a reference. Firstly, the IC50 of
Sunitinib for MDA-MB-231 (IC50= 4.8 μM ± 0.7) and for MCF-7
(5.2 μM ± 0.5) was established (Fig. 5A and B). While both cell lines
were similarly sensitive to Sunitinib (Fig. 5A and B), none of them was
sensitive to Erlotinib, even at the highest soluble concentration of
10 μM [47] (Supplementary Fig. 5A and B). Notably, MCF-7 cells were
more sensitive to both Vps34 inhibitors as compared to MDA-MB-
231 cells (Fig. 5A and B). We then assessed the effect of combination
treatment in both cell lines using IC20 concentrations of SB02024, PIK-
III and CQ. Addition of either Vps34 inhibitor to Sunitinib significantly
decreased cell viability in both cell lines (Fig. 5C and D). However, CQ
had a significant effect on cell viability only in MCF-7 cells when
combined with Sunitinib (Fig. 5D). While the addition of Vps34 in-
hibitors or CQ did not sensitize MDA-MB-231 cells to Erlotinib
(Supplementary Fig. S5C), the three compounds enhanced the effect of
Erlotinib in MCF-7 cells (Supplementary Fig. S5D). Using the clono-
genic assay, we further assessed the efficacy of the combination treat-
ment. For this assay, only MCF-7 cells were used as MDA-MB-231 cells
did not form distinct colonies. Strikingly, both Vps34 inhibitors, as well
as CQ, significantly potentiated the efficacy of Sunitinib or Erlotinib in
reducing clonogenic cell survival (Fig. 5E and F and Supplementary Fig.
S5E, F).
Finally, we examined whether these drug combinations would be
similarly effective in MDA-MB-231 and MCF-7 cells grown as multi-
cellular spheroids (MCS). We chose to do these experiments with
Sunitinib only as both breast cancer cell lines were highly resistant to
Erlotinib. Cells grown as MCS were previously reported to activate
autophagic flux [48,49] as well as partially recapitulate therapy re-
sistance, so-called multicellular resistance [50,51]. Autophagy induc-
tion in MCS as compared to monolayer cultures was monitored using
Western blot analysis and revealed a decrease in the autophagic sub-
strate NCOA4 and p62 in the MDA-MB-231, while LC3B-II was in-
creased in the presence of BafA1 in MCF-7 MCS, suggesting, although
differential, an autophagy induction in either cell line when grown as
MCS (Supplementary Fig. S6A, B). In line with data in Fig. 4, SB02024
inhibited autophagic flux in both monolayer cultures and MCS in either
cell line although to a different extent (Supplementary Fig. S6A, B). In
MDA-MB-231 MCS, combined treatment with Sunitinib and PIK-III
significantly decreased relative cell viability as compared to the Suni-
tinib treatment alone (Fig. 5G). In MCF-7 MCS, the combination of
either SB02024 or PIK-III significantly decreased relative cell viability
as compared to Sunitinib alone (Fig. 5H). Interestingly, CQ did not
enhance the cytotoxicity of Sunitinib in either of the cell lines grown as
MCS. Taken together, the data provide compelling evidence that au-
tophagy inhibition by small molecule inhibitors of Vps34 increases the
cytotoxic effects of Sunitinib and Erlotinib as summarised in Fig. 5I.
4. Discussion
In this study, we performed a high-content screening to monitor
autophagy induction by anti-cancer drugs and focused on two tyrosine
kinase inhibitors, Sunitinib and Erlotinib. We found that Sunitinib and
Erlotinib induced autophagy in our screening system as well as in breast
cancer cell lines. Furthermore, inhibition of Vps34 could potentiate the
cytotoxic effect of these drugs. Also, we report a novel Vps34 inhibitor,
namely SB02024, that was able to decrease tumor growth in vivo in-
dicating its potential to be developed into a drug for anti-cancer
treatment.
We addressed the question of which anti-cancer drugs can induce
autophagy in cancer cells. Being fully aware of the limitations of the
screening system, such as cell-type specificity and in vitro conditions, we
have tested a library of anti-cancer drugs in a high content phenotypic
screen for autophagy induction to identify more than 1/3 of these drugs
being able to induce autophagy. This approach has been used before in
a screen of the Institute of Chemistry and Cell Biology (ICCB) library of
bioactive compounds and the National Cancer Institute (NCI) me-
chanistic set library [52]. Our screen of the FIMM drug library, on the
other hand, provides data better applicable for translational research:
this comprehensive drug library contains most of the clinical and pre-
clinical anti-cancer drugs in physiologically relevant concentrations
[32]. We also used a genetic approach to inhibit autophagy in the same
screening system to identify drugs whose efficacy was increased by
autophagy inhibition. The siRNA-mediated knockdown of ATG7 and
VPS34 might be suboptimal for autophagy inhibition due to transient
nature of RNAi approach, the dynamic nature of autophagy [53] or to
the interaction between autophagy and intracellular siRNA delivery
[54]. Thus, the number of drugs confirmed to induce a cytoprotective
autophagy might be underestimated. Using this approach, we identified
two tyrosine kinase inhibitors that we further investigated in combi-
nation with autophagy inhibition in cellular models of breast cancer.
For this purpose, we inhibited autophagy pharmacologically, using
highly specific small molecule inhibitors of Vps34, SB02024 and PIK-III.
Several studies have previously demonstrated that induction of autop-
hagy may represent a mechanism for drug resistance [14,15,55]. In-
deed, autophagy, as a conserved cellular response to stress, can be a
powerful protector against cell-damaging drugs [56]. Also novel tar-
geted therapies, similarly to established cytotoxic drugs, induce mul-
tiple resistance mechanisms, including induction of autophagy, and
therefore may be inefficient against cancer as a monotherapy [1,56].
Induction of autophagy as an intrinsic property of some targeted
therapies may thus be one of the reasons for ineffective clinical trials.
For example, the two tyrosine kinase inhibitors that we focused on,
Sunitinib and Erlotinib, have shown poor clinical efficacy in breast
cancer patients [57,58]. Initially, Sunitinib showed promising results in
phase II clinical trials [59] but failed to prolong survival in phase III
trials in metastatic and triple-negative breast cancer [60–62]. This
prompted us to assess whether autophagy induction might contribute to
this lack of a prolonged response. Indeed, in this study, a combination
with Vps34 inhibitors significantly increased the sensitivity of breast
cancer cells to Sunitinib. Moreover, while these cells were initially very
resistant to Erlotinib alone, Vps34 inhibition could overcome this re-
sistance. Further animal studies will allow concluding whether autop-
hagy inhibition can improve the anti-cancer properties of these tyrosine
kinase inhibitors for the treatment of breast cancer.
Another important question that we have not addressed in this study
is the mechanism of autophagy induction by the tyrosine kinase
Table 1
Selectivity profile of SB02024 and PIK-III. Kd values are reported in μM and
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Fig. 4. Vps34 inhibitor SB02024 blocks autophagic flux in vitro and decreases tumor growth of breast cancer xenografts. (A) Fluorescence microscopy
images of GFP + puncta area of H1299 cells expressing GFP-2XFYVE treated for 6 h with DMSO, 0,5 μM KU-0063794 (KU) or 0,7 μM SB02024. Scale bar: 50 μm. (B)
Quantification of the experiment in (A). Values were normalized to DMSO control. Means ± SD of three independent experiments are shown. (C) Fluorescence
microscopy images of GFP + puncta area of HOS cells expressing GFP-LC3 treated either with DMSO alone or with the combination of 10 μM KU and 10 nM BafA1 in
the presence or absence of 1,1 μM SB02024. Scale bar: 50 μm. (D) Quantification of the experiment in (C). Values were normalized to the combination of
DMSO + KU + BafA1. Means ± SD of three independent experiments are shown. MDA-MB-231 (E) and MCF-7 (F) cells were treated with DMSO or SB02024 at
indicated concentrations for 24 h 50 nM BafA1 was added for the last 2 h of treatment. The effect on autophagic flux was measured by assessing levels of Vps34,
NCOA4, p62, and LC3B-II using Western blotting. β-actin was used as a loading control. A representative blot of three independent experiments is shown.
Quantification of the band intensity using Image J is indicated below. (G) Tumor growth of MDA-MB-231 subcutaneous xenografts treated with vehicle or SB02024
(20mg/kg or 50mg/kg, daily) for 30 days. Means ± SEM, n= 10. (H) Tumor growth of orthotopic MCF-7 xenografts treated with vehicle (n = 6), 20 mg/kg
SB02024 (n = 6) or 50 mg/kg SB02024 (n = 5, n = 4 for last measurement) for 21 days. Means ± SEM are shown; *P < 0.05, **P < 0.01, ***P < 0.001;
Tukey's multiple comparisons test.
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inhibitors. Activated tyrosine-kinases support tumor cell growth and
survival via several downstream signalling pathways including PI3K/
AKT/mTOR pathway. Thus, inhibition of tyrosine kinases will in-
evitably result in the inhibition of mTOR, which consequently leads to
the induction of autophagy [56].
It has been shown that the lysosomal sequestration of Sunitinib may
result in the permeabilization of the lysosomal membrane leading to
cell death [63,64]. Notably, combination treatments with lysosomal
inhibitors have been reported to increase the sensitivity to Sunitinib in
several cancer types [41,65]. Another mechanism involving modulation
of the anti-apoptotic protein MCL-1 and, again, of the mTOR protein by
Sunitinib has also been described to alter autophagic flux [66]. Further
studies will be necessary to dissect the exact mechanisms of autophagy
activation by each of the tyrosine kinase inhibitors to use this knowl-
edge for the development of novel combination therapies.
Similar to our study, combinations of Vps34 inhibitor with other
anti-cancer drugs have been assessed. For example, Vps34 inhibitor
SAR405 was able to increase sensitivity to cisplatin of human urothelial
carcinoma [67] and head and neck cancer cell lines [68] while a dual
FGFR inhibitor also targeting Vps34 increased cisplatin sensitivity of
bladder cancer cells [69]. Also, genetic inhibition of Vps34 increased
the sensitivity of HER + breast cancer cell lines to class I PI3K or HER2
inhibitors [70]. Collectively, these and our findings strongly support
Vps34 as a target in anti-cancer treatment.
Conventional two dimensional (2D) cell culture systems are often
poorly predictive of drug efficacy, as we and others have shown
[71,72]. Indeed, the growth of tumor cells as MCS better mimics the
architecture of tumors and more closely reproduces the heterogeneity
of tumor tissue in terms of phenotypic and metabolic features [51,73],
which have a crucial impact on therapeutic efficacy [51,72,74,75].
Moreover, cells grown in 3D encounter metabolic stress that in turn
may stimulate autophagy, as it was shown in different cancer models
[48,49]. Remarkably, even in MCS, being as a rule more resistant to
drug treatments, the addition of Vps34 inhibitors potentiated the cy-
totoxic effect of Sunitinib. This model system also clearly showed that
the potent additive effects of CQ in the monolayer culture (based on
viability and colony formation assays) are diminished in MCS, most
likely due to hypoxia and acidosis characterizing MCS and low activity
of CQ in these conditions [75]. Interestingly, there is another aspect of
targeting Vps34 in conjunction with Sunitinib. Apart from induction of
autophagy, hypoxia may represent an important mechanism mediating
resistance to Sunitinib [58,76]. Thus, targeting hypoxia was shown to
increase the therapeutic efficacy of Sunitinib in vivo [77]. At the same
time, targeting Vps34 has been recently shown to inhibit oxygen con-
sumption rate [69,78], raising the possibility that Vps34 inhibition may
decrease in vivo hypoxia and contribute to improving Sunitinib sensi-
tivity. This further strengthens the notion that using Vps34 inhibitors in
combination with targeted tyrosine kinase inhibitor-based therapy, and
particularly Sunitinib, can overcome resistance and emphasizes their
value in cancer treatment.
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